Expression of Concern
This article is currently under investigation. We strongly recommend that this article is not cited until the investigation is completed.
Research Paper Volume 13, Issue 11 pp 15285—15306

Mesenchymal stem cells-derived extracellular vesicles ameliorate Alzheimer’s disease in rat models via the microRNA-29c-3p/BACE1 axis and the Wnt/β-catenin pathway

class="figure-viewer-img"

Figure 1. BM-MSC-EVs have therapeutic effects on AD rats. The rat model of AD was established by injection of Aβ1-42, and then rats were treated with BM-MSC-EVs, with injection of equal volume of BM-MSC conditioned medium after GW4869 treatment as the control. (A) Rat behaviors and memory abilities were measured using Morris Water maze test; (B) Thioflavin S staining for Aβ deposition in cerebral cortex and hippocampus of rats in each group; (C) Immunofluorescence assay was used to detect Aβ content in cerebral cortex and hippocampus of rats in each group; (D) ELISA was used to detect Aβ1-42 level in cerebral cortex and hippocampus and levels of inflammatory cytokines (IL-1β, IL-6 and TNF-α) in cerebral tissues of rats in each group; (E) WB was used to detect the protein levels of NEP and IDE; (F) RT-qPCR was used to detect the mRNA expression of NEP and IDE. n = 6. Data were expressed as mean ± standard deviation. Data were analyzed using one-way ANOVA followed by Tukey’s multiple comparisons test. In panel (A) ***p < 0.001 (WT vs AD), ### p < 0.001 (AD-NC vs AD-EVs). In other panels, *p < 0.05, **p < 0.01, ***p < 0.001.